Tamara G. Ayrapetova
Tamara G. Ayrapetova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anton Grigor'EVich Milakin
National Medical Research Centre for Oncology
4 shared publications - Dmitriy Akimovich Kharagezov
National Medical Research Centre for Oncology
4 shared publications - Ellada A. Mirzoyan
National Medical Research Centre for Oncology
4 shared publications - Oleg Nikolaevich Stateshnyy
National Medical Research Centre for Oncology
4 shared publications - Arthur A. Antonyan
National Medical Research Centre for Oncology
3 shared publications - Igor' Aleksandrovich Leyman
National Medical Research Centre for Oncology
3 shared publications
Latest Publications
- Open Access
- 25 February 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (1) , 56-62
Cellular Immunity in Patients With Small Cell Lung Cancer in Presence and Absence of Circulating Tumor Cells
Background: Circulating tumor cells (CTCs) play an important role in hematogenous metastasis of malignant tumors. Small cell lung cancer (SCLC) is the most aggressive form of lung cancer with the highest number of detected CTCs.Objective: To evaluate the presence and number of CTCs as an immunosuppression factor in SCLC.Materials and methods: In 30 patients with stage III-IV SCLC, CTCs were detected using the CellSearch system (Veridex LLC, Belgium) before treatment. The participants were divided into groups based on presence of CTCs. Flow cytometry was used to assess T- and natural killer (NK)-cellular components of the immune system and revealed that the CTC presence in patients with SCLCwas accompanied by low levels of NK cells expressing CD335+, granzyme B, and perforin and lower levels of helper T cells with markers of early activation (CD38 and CD69). Lower levels of CD8+CD69+ activated cytotoxic T cells were observed with the highest level of CTCs (>50). Thus, a decrease in the quantitative and functional parameters of T and NK cells in presence of CTCs can be regarded as one of the immunosuppression factors in patients with SCLC.Results: The presence of CTCs, regardless of their number in the blood of patients with SCLC, is characterized by suppression of the innate immune system: decreased functional activity of NK cells, which, even with the preservedtotal number of NK cells, leads to a decrease in their antitumor potential and is often observed in case of widespread metastases. A similar pattern was noted in the analysis of the adaptive immune system, namely, the T cells.Conclusions: As with other malignant tumors, the presence of CTCs in patients with SCLC can be regarded as one of the immunosuppression factors.
- 25 February 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (1) , 56-62
Open AccessCellular Immunity in Patients With Small Cell Lung Cancer in Presence and Absence of Circulating Tumor Cells
Background: Circulating tumor cells (CTCs) play an important role in hematogenous metastasis of malignant tumors. Small cell lung cancer (SCLC) is the most aggressive form of lung cancer with the highest number of detected CTCs.Objective: To evaluate the presence and number of CTCs as an immunosuppression factor in SCLC.Materials and methods: In 30 patients with stage III-IV SCLC, CTCs were detected using the CellSearch system (Veridex LLC, Belgium) before treatment. The participants were divided into groups based on presence of CTCs. Flow cytometry was used to assess T- and natural killer (NK)-cellular components of the immune system and revealed that the CTC presence in patients with SCLCwas accompanied by low levels of NK cells expressing CD335+, granzyme B, and perforin and lower levels of helper T cells with markers of early activation (CD38 and CD69). Lower levels of CD8+CD69+ activated cytotoxic T cells were observed with the highest level of CTCs (>50). Thus, a decrease in the quantitative and functional parameters of T and NK cells in presence of CTCs can be regarded as one of the immunosuppression factors in patients with SCLC.Results: The presence of CTCs, regardless of their number in the blood of patients with SCLC, is characterized by suppression of the innate immune system: decreased functional activity of NK cells, which, even with the preservedtotal number of NK cells, leads to a decrease in their antitumor potential and is often observed in case of widespread metastases. A similar pattern was noted in the analysis of the adaptive immune system, namely, the T cells.Conclusions: As with other malignant tumors, the presence of CTCs in patients with SCLC can be regarded as one of the immunosuppression factors.
- Open Access
- 14 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 38-45
A case of a fifteen-year-old patient suffering from rare adenocystic lung carcinoma bronchoplastic surgery
Adenoid cystic carcinoma of the lung is a relatively rare malignant tumor, accounting for 0.04–0.2 % of all primary malignant tumors of the respiratory system. This carcinoma can occur at any age, but it is more common in the 40–60 age group and usually in women. The main treatment method for adenoid cystic carcinoma is surgical. Since tumors of this histological form are often centrally located, options for bronchoplastic operations are considered. In childhood, adenoid cystic carcinoma is extremely rare, and performing bronchoplastic lobectomies in children is associated with several difficulties, such as the smaller diameter of the bronchi compared to adult patients, complicating surgical intervention and subsequent rehabilitation. This clinical case demonstrates the experience of performing a bronchoplastic operation on a 15-year-old patient at the Department of Thoracic Oncology of the National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. The patient was hospitalized complaining of prolonged cough, shortness of breath, and chest pain. Adenoid cystic carcinoma of the central type was identified during diagnostics, which included bronchoscopy, computed tomography, and biopsy. The surgical intervention involved performing a bronchoplastic lobectomy, during which the affected lobe of the lung was removed with resection and reconstruction of the bronchus. The operation was performed taking into account the anatomical features of the child's body, which required high precision and surgical skills. The postoperative period proceeded without significant complications, and the patient was under the supervision of a multidisciplinary team of specialists.This clinical case provides a detailed description of the results of preoperative diagnostic measures, the stages of the operation, and the postoperative follow-up results. Special attention was paid to the difficulties associated with the small diameter of the bronchi in children, which required the use of specialized instruments and techniques. The importance of using modern diagnostic and treatment methods, as well as close interdisciplinary interaction, is emphasized for a successful treatment outcome.The experience of performing such operations in childhood is extremely important for improving the quality and safety of surgical treatment of adenoid cystic carcinoma and other rare tumors in children. Further observations will be described in stages.
- 14 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 38-45
Open AccessA case of a fifteen-year-old patient suffering from rare adenocystic lung carcinoma bronchoplastic surgery
Adenoid cystic carcinoma of the lung is a relatively rare malignant tumor, accounting for 0.04–0.2 % of all primary malignant tumors of the respiratory system. This carcinoma can occur at any age, but it is more common in the 40–60 age group and usually in women. The main treatment method for adenoid cystic carcinoma is surgical. Since tumors of this histological form are often centrally located, options for bronchoplastic operations are considered. In childhood, adenoid cystic carcinoma is extremely rare, and performing bronchoplastic lobectomies in children is associated with several difficulties, such as the smaller diameter of the bronchi compared to adult patients, complicating surgical intervention and subsequent rehabilitation. This clinical case demonstrates the experience of performing a bronchoplastic operation on a 15-year-old patient at the Department of Thoracic Oncology of the National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. The patient was hospitalized complaining of prolonged cough, shortness of breath, and chest pain. Adenoid cystic carcinoma of the central type was identified during diagnostics, which included bronchoscopy, computed tomography, and biopsy. The surgical intervention involved performing a bronchoplastic lobectomy, during which the affected lobe of the lung was removed with resection and reconstruction of the bronchus. The operation was performed taking into account the anatomical features of the child's body, which required high precision and surgical skills. The postoperative period proceeded without significant complications, and the patient was under the supervision of a multidisciplinary team of specialists.This clinical case provides a detailed description of the results of preoperative diagnostic measures, the stages of the operation, and the postoperative follow-up results. Special attention was paid to the difficulties associated with the small diameter of the bronchi in children, which required the use of specialized instruments and techniques. The importance of using modern diagnostic and treatment methods, as well as close interdisciplinary interaction, is emphasized for a successful treatment outcome.The experience of performing such operations in childhood is extremely important for improving the quality and safety of surgical treatment of adenoid cystic carcinoma and other rare tumors in children. Further observations will be described in stages.
- Open Access
- 13 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 58-70
The role of tumor stem cells and the immune microenvironment in the pathogenesis of lung cancer: mechanisms of interaction and research prospects
Despite significant advances in the treatment of malignant neoplasms, the issue of therapy resistance mediated by cancer stem cells (CSCs) necessitates the development of new treatment strategies. Studying the role of CSCs and the immune microenvironment in the pathogenesis of cancer, particularly non-small cell lung cancer (NSCLC), is a pressing issue in modern oncology. This paper is based on an extensive analysis of recent research and aims to study the mechanisms underlying the development of NSCLC.The origin of CSCs, their markers, and the main signaling pathways involved in regulating their activity are considered. Special attention is paid to the influence of CSCs on the progression of lung cancer and the mechanisms underlying their therapy-mediated resistance. Various approaches to treating lung cancer targeting CSCs, focusing on targeted therapy aimed at specific molecular targets, are highlighted.The important role of the tumor immune microenvironment in the pathogenesis of lung cancer and its impact on CSCs is emphasized. Mechanisms of immune response regulation in tumors and the potential use of immunotherapy to improve lung cancer treatment outcomes are discussed. The article also reviews modern diagnostic and treatment methods, including molecular-genetic and immunohistochemical approaches.This paper work represents a review of current knowledge on the mechanisms of lung cancer development and is significant for understanding tumor biology and developing new treatment methods. The need for an interdisciplinary approach and comprehensive use of modern diagnostic and therapeutic methods to improve the prognosis and survival rates of NSCLC patients is emphasized. Special attention is given to the prospects of using combined therapeutic approaches, including targeted drugs and immunotherapy, aimed at suppressing CSC activity and modifying the tumor microenvironment.In conclusion, a deep understanding of the molecular mechanisms regulating CSC activity and their interaction with the tumor microenvironment opens new opportunities for developing effective treatment strategies. This review underscores the need for further research in this area to ensure more successful treatment and improved quality of life for lung cancer patients.
- 13 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 58-70
Open AccessThe role of tumor stem cells and the immune microenvironment in the pathogenesis of lung cancer: mechanisms of interaction and research prospects
Despite significant advances in the treatment of malignant neoplasms, the issue of therapy resistance mediated by cancer stem cells (CSCs) necessitates the development of new treatment strategies. Studying the role of CSCs and the immune microenvironment in the pathogenesis of cancer, particularly non-small cell lung cancer (NSCLC), is a pressing issue in modern oncology. This paper is based on an extensive analysis of recent research and aims to study the mechanisms underlying the development of NSCLC.The origin of CSCs, their markers, and the main signaling pathways involved in regulating their activity are considered. Special attention is paid to the influence of CSCs on the progression of lung cancer and the mechanisms underlying their therapy-mediated resistance. Various approaches to treating lung cancer targeting CSCs, focusing on targeted therapy aimed at specific molecular targets, are highlighted.The important role of the tumor immune microenvironment in the pathogenesis of lung cancer and its impact on CSCs is emphasized. Mechanisms of immune response regulation in tumors and the potential use of immunotherapy to improve lung cancer treatment outcomes are discussed. The article also reviews modern diagnostic and treatment methods, including molecular-genetic and immunohistochemical approaches.This paper work represents a review of current knowledge on the mechanisms of lung cancer development and is significant for understanding tumor biology and developing new treatment methods. The need for an interdisciplinary approach and comprehensive use of modern diagnostic and therapeutic methods to improve the prognosis and survival rates of NSCLC patients is emphasized. Special attention is given to the prospects of using combined therapeutic approaches, including targeted drugs and immunotherapy, aimed at suppressing CSC activity and modifying the tumor microenvironment.In conclusion, a deep understanding of the molecular mechanisms regulating CSC activity and their interaction with the tumor microenvironment opens new opportunities for developing effective treatment strategies. This review underscores the need for further research in this area to ensure more successful treatment and improved quality of life for lung cancer patients.
- Open Access
- 13 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 14-19
Research on the expression of E-cadherin in lung cancer tumors with different histological structures
Purpose of the study. To conduct a comparative analysis of E-cadherin expression in inoperable patients with non-small cell lung cancer (NSCLC) cells and with different survival rates.Materials and methods. The study included 96 patients with inoperable NSCLC: 84 (87.5 %) men and 12 (12.5 %) women, whose average age was 62.4 ± 0.68 years. Squamous cell carcinoma (SCC) was diagnosed in 78 (81.25 %) patients, and adenocarcinoma (AC) with a tumor differentiation grade of G2-G3 in 18 (18.75 %). The patients were treated and monitored at the National Medical Research Centre for Oncology. The expression of cadherins was determined in the tumor cells of the biopsy specimens. The obtained data have been processed using the Statistica 13.0 program (StatSoftInc., USA). The studied data have been checked for compliance with the normal distribution using the Shapiro-Wilk criterion.Results. The following distribution of patients with NSCLC was noted: IIA – 2 (2.1 %), IIB – 14 (14.6 %), IIIA – 51 (53.1 %), IIIB – 29 (30.2 %), i. e. the frequency of stage III is higher than stage II (83.3 % (n = 80) versus 16.7 % (n = 16), p < 0.001). Fatal outcome occurred in the SCC group within 1 year in 28 patients, within 1 to 2 years – in 30, 20 patients survived for 3 years or more. For AC, these figures were 6,5 and 7 respectively. The analysis revealed that E-cadherin expression was noted in both squamous cell carcinoma and lung adenocarcinoma: Me 55 [LQ 37; UQ 65] and Me 50 [LQ 40; UQ 70], respectively.Conclusions. 1. The analysis revealed that E-cadherin expression was observed in both squamous cell carcinoma and lung adenocarcinomas without statistically significant differences between the compared groups (p = 0.25). 2. Statistically significant differences in the levels of E-cadherin expression were noted in the biopsy samples of the 2 groups only with survival up to 1 year and up to 3 years or more (p < 0.05).
- 13 November 2024
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 14-19
Open AccessResearch on the expression of E-cadherin in lung cancer tumors with different histological structures
Purpose of the study. To conduct a comparative analysis of E-cadherin expression in inoperable patients with non-small cell lung cancer (NSCLC) cells and with different survival rates.Materials and methods. The study included 96 patients with inoperable NSCLC: 84 (87.5 %) men and 12 (12.5 %) women, whose average age was 62.4 ± 0.68 years. Squamous cell carcinoma (SCC) was diagnosed in 78 (81.25 %) patients, and adenocarcinoma (AC) with a tumor differentiation grade of G2-G3 in 18 (18.75 %). The patients were treated and monitored at the National Medical Research Centre for Oncology. The expression of cadherins was determined in the tumor cells of the biopsy specimens. The obtained data have been processed using the Statistica 13.0 program (StatSoftInc., USA). The studied data have been checked for compliance with the normal distribution using the Shapiro-Wilk criterion.Results. The following distribution of patients with NSCLC was noted: IIA – 2 (2.1 %), IIB – 14 (14.6 %), IIIA – 51 (53.1 %), IIIB – 29 (30.2 %), i. e. the frequency of stage III is higher than stage II (83.3 % (n = 80) versus 16.7 % (n = 16), p < 0.001). Fatal outcome occurred in the SCC group within 1 year in 28 patients, within 1 to 2 years – in 30, 20 patients survived for 3 years or more. For AC, these figures were 6,5 and 7 respectively. The analysis revealed that E-cadherin expression was noted in both squamous cell carcinoma and lung adenocarcinoma: Me 55 [LQ 37; UQ 65] and Me 50 [LQ 40; UQ 70], respectively.Conclusions. 1. The analysis revealed that E-cadherin expression was observed in both squamous cell carcinoma and lung adenocarcinomas without statistically significant differences between the compared groups (p = 0.25). 2. Statistically significant differences in the levels of E-cadherin expression were noted in the biopsy samples of the 2 groups only with survival up to 1 year and up to 3 years or more (p < 0.05).